Journal of Oncology / 2012 / Article / Tab 2 / Research Article
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence Table 2 Ongoing a phase III clinical trials evaluating the addition of bevacizumab for the treatment of advanced breast cancer.
Identifier Setting
𝑛
Study Design NCT00600340 Advanced 560 Bevacizumab + paclitaxel versus bevacizumab + capecitabine NCT01303679 Advanced 198 Bevacizumab + exemestane versus bevacizumab + paclitaxel NCT01131195 Advanced 142 Bevacizumab + paclitaxel versus metronomic ctx + capecitabine NCT01250379 Advanced 488 Chemotherapy + bevacizumab. versus chemotherapy* NCT00929240 Advanced Bevacizumab + capecitabine. versus bevacizumab** NCT00785291 Advanced 900 Bevacizumab + paclitaxel versus paclitaxel NCT01200212 Advanced 432 Bevacizumab + taxane + capecitabine versus taxane + capecitabine NCT00545077 Advanced 378 Letrozole or fulvestrant versus letrozole or fulvestrant + bevacizumab NCT00601900 Advanced 502 Tamoxifen or letrozole versus tamoxifen or letrozole + bevacizumab NCT00391092 Advanced 407 Bevacizumab + trastuzumab + docetaxel versus trastuzumab + docetaxel NCT00520975 Advanced 489 Bevacizumab + trastuzumab + carboplatin + paclitaxel versus trastuzumab + carboplatin + paclitaxel
Identifiers are from clinicaltrials.gov website. *Patients previously treated with bevacizumab. **Patients treated with bevacizumab and docetaxel and no evidence of progressive disease.
𝑛
: estimated number of patients.
